37 results about "Proteus penneri" patented technology

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. With these methods, bacteria can be detected (universal primers and / or probes) and identified (species-specific primers and / or probes) directly from the clinical specimens or from an isolated bacterial colony. Bacteria are further evaluated for their putative susceptibility to antibiotics by resistance gene detection (antibiotic resistance gene specific primers and / or probes). Diagnostic kits for the detection of the presence, for the bacterial identification of the above-mentioned bacterial species and for the detection of antibiotic resistance genes are also claimed. These kits for the rapid (one hour or less) and accurate diagnosis of bacterial infections and antibiotic resistance will gradually replace conventional methods currently used in clinical microbiology laboratories for routine diagnosis. They should provide tools to clinicians to help prescribe promptly optimal treatments when necessary. Consequently, these tests should contribute to saving human lives, rationalizing treatment, reducing the development of antibiotic resistance and avoid unnecessary hospitalizations.

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony.

The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating infections and diseases using anti-flagellin antibodies in humans, other animals and birds.

The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.

The present invention relates to new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribionucleic acid (rRNA) or rRNA genes, to be used for the specific detection and / or identification of Proteus species, in particular of Proteus mirabilis, Proteus vulgaris and / or Proteus penneri in a biological sample.The present invention relates also to a method for the specific detection and / or identification of Proteus species, in particular Proteus mirabilis, Proteus vulgaris and / or Proteus penneri, using said new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region.It relates also to nucleic acid primers to be used for the amplification of said spacer region of Proteus species in a sample.

The suppository for treating bacterial vaginitis contains total phellodendron alkaloid and volatile atractylodes rhizome oil in the weight ratio of 1 to 1.6. The suppository has the effects of resisting bacteria, resisting fungi, resisting vagina trichomonad, resisting inflammation, relieving pain and stopping itch and can reach the effect of curing bacterial vaginitis radically. Pharmacological experiments show that the suppository comprehensive curative effect higher than that of any one kind of chemical medicine. The suppository has obvious inhibiting and deactivating effect on common vagina infecting bacteria, such as escherichia coli, Staphylococcos aureus, bacillus pyocyaneus, etc. Pharmacological experiments proves the use of the composition of total phellodendron alkaloid and volatile atractylodes rhizome oil in treating bacterial vaginitis.

The present invention relates to a combined bacterial vaccine for curing allergic diseases of allergic rhinitis, allergic conjunctivitis, various bronchitis and asthma and deafness resulted from medicine with good therapeutic effect. Said combined bacterial vaccine is formed from diplococcus pneumoniae, alpha-hemolytic streptococcus, beta-hemolytic streptococcus, staphylococuus aureus, staphylococcus epidermidis and others.

The present invention relates to a combined bacterial vaccine for curing allergic diseases of allergic rhinitis, allergic conjunctivitis, various bronchitis and asthma and deafness resulted from medicine with good therapeutic effect. Said combined bacterial vaccine is formed from diplococcus pneumoniae, alpha-hemolytic streptococcus, beta-hemolytic streptococcus, staphylococuus aureus, staphylococcus epidermidis and others.

The invention provides a new bacterial strain-proteus penneri CA8 for generating coenzyme Q10 and applications of the proteus penneri CA8 in preparation of the coenzyme Q10 by microbial fermentation. The bacterial strain is preserved in China Center for Type Culture Collection, the address is 430072, Wuhan University, Wuhan, China, the preservation number is CCTCC No: M2012208, and the preservation date is June 10, 2012. The new bacterial strain-proteus penneri CA8 for generating the coenzyme Q10 has the following main beneficial effects: the new coenzyme Q10 producing strain is provided, and the coenzyme Q10 is prepared by utilizing the microbial fermentation of the strain, so that yield is high, the subsequent extraction method is simple, and the industrial production is facilitated.

The invention relates to an amylase, in particular to a fermentation production method and an application of a high-yield exopolysaccharide strain and an amylase thereof. The strain is a proteus penneri PZ-1. The method comprises the following steps: inoculating a culture medium with the roteus penneri PZ-1; fermenting the culture medium to obtain fermentation culture fluid; cooling and centrifuging the fermentation culture fluid to remove a strain body; getting supernatant fluid; precipitating the supernatant fluid with industrial alcohol; standing still precipitate liquid is obtained; centrifuging the precipitate liquid and taking out a precipitate to obtain crude amylase; and purifying the crude amylase to obtain exopolysaccharide. Proved by a series of experiments, the strain has the proteus characteristics, is used for producing the exopolysaccharide with high yield, and has obvious effects on improving immunity and capability to resist diseases; and the exopolysaccharide producedby fermentation can be used for preparing veterinary injecta, veterinary powder, feed additives, an immunologic adjuvant and functional raw material of healthcare foods.

The invention discloses application of aspongopus total alkaloids in preparation of medicines or health care products with antibacterial, anti-inflammatory, antipyretic and immunological enhancement functions. The biological activity detection result of the aspongopus total alkaloids proves that the aspongopus total alkaloids have the inhibition effects of different degrees on diplococcus pneumoniae, staphylococcus aureus, type A streptococcus pyogens, type B streptococcus pyogens and proteusbacillus vulgaris, have obvious inhibition effects on the diplococcus pneumoniae and staphylococcus aureus, have the obvious anti-inflammatory effect on ear swell of mice caused by dimethylbenzene and have the obvious antipyretic effect on exothermic reaction of rats caused by dried yeasts, the phagocytic function of the reticuloendothelial system of the mice can be obviously enhanced, and the aspongopus total alkaloids have the immunological enhancement function and are low in toxicity and safe to use.

This invention describes a bacillus subtilis and the process for preparing its compound pharmaceutics. The bacillus subtilis is conserved at China General Microbiological Culture Collection Center of China Committee of Culture Collection for Microorganisms, the name is: Bacillus subtilis LY-35 and the conservation number is: CGMCC No. 1222. The pharmaceutics is a compound of the bacteriophages of such pathogens as bacillus subtilis, Staphylococcus, Streptocoaus, colibacillus, proteus, pseudomonas, salmonella, shigella, pasteurella and klebsiella. The pharmaceutics can prevent and treat the diseases caused by pathogens, and can be a non-polluted, high therapeutic effectiveness and safe substitute for antibiotics.

The invention relates to a screening and identification method of an electricigen enzyme and relates to a microbial enzyme. The method comprises the following steps: getting a genome message by proteomic analysis, and designing a random primer to perform gene cloning so as to get two brand new proteins, wherein the two brand new proteins are determined as laccase and porin F of Proteus penneri ATCC (American type culture collection) 35198 by comparison, and the amino acid similarity of each is 87.8% and 84.4% respectively. The laccase of electrogenesis Proteus and the enzyme activity characteristic, as well as the laccase and a porin gene are reported; and studies find that the enzyme activity of 269.2U / g-DCW can be obtained by using 2.5mmol / L of copper sulfate to perform induction production on the laccase, and the enzyme activity is improved by 30.6 times in comparison with that without induction. The invention provides a screening and protein identification method of a novel enzyme of an electricigen, which is expected to be applied to easing the crisis of growing shortage of petrochemical fuel and reducing the emission of carbon dioxide.